A number of other brokerages have also weighed in on MRUS. Zacks Investment Research upgraded Merus from a hold rating to a buy rating and set a $15.00 price objective for the company in a research note on Friday, March 15th. Citigroup reduced their target price on Merus from $18.00 to $16.00 and set a neutral rating on the stock in a report on Friday, March 15th. Royal Bank of Canada raised Merus from a sector perform rating to an outperform rating and increased their target price for the stock from $18.00 to $23.00 in a report on Wednesday, April 3rd. Guggenheim initiated coverage on Merus in a report on Friday. They set a buy rating and a $25.00 target price on the stock. Finally, ValuEngine downgraded Merus from a hold rating to a sell rating in a report on Monday, February 4th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $23.00.
Shares of NASDAQ MRUS opened at $16.45 on Friday. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74. The company has a market cap of $349.21 million, a price-to-earnings ratio of -8.94 and a beta of -0.06.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
See Also: How to invest in a bear market
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.